An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2-5 Years With Perennial Allergic Rhinitis

NCT00132925 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

460

Enrollment

INDUSTRY

Sponsor class

Conditions

Rhinitis, Allergic, Perennial

Interventions

DRUG: Triamcinolone

Sponsor

Sanofi